ANNEXON

We are focused on stopping C1q, the initiating molecule of the classical complement pathway, at the start to treat devastating autoimmune, neurodegenerative, and ophthalmic diseases of the body, brain and eye... We are passionate about delivering transformative therapies for people suffering from devastating complement-driven diseases.

Also known as: Annexon, Inc.

Primary location: Brisbane United States